Drug-drug Interaction,SHR3680
Conditions
Brief summary
The DDI study had been designed to investigate the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium and metformin hydrochloride
Interventions
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
To observe the effect of SHR3680 on the pharmacokinetics of digoxin, Rosuvastatin calcium, metformin hydrochloride and to evaluate the safety. The subjects will take digoxin, Rosuvastatin calcium, metformin hydrochloride at first single dose, then wash out ,and take it at second time together with SHR3680 after multiple administration of SHR3680
Eligibility
Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Subjects must meet all of the following criteria to enter the study: 1. 18 ≤ age ≤75, male; 2. ECOG score of physical condition is 0 \ 1; 3. The expected survival time is at least 3 months; 4. Prostate adenocarcinoma confirmed by histological or cytological examination (can be included in mHSPC and mCRPC populations), with no neuroendocrine or small-cell characteristics;CRPC should also meet the following two conditions :(1) serum testosterone level of castration (\< 1.7 nmol/L);(2) biochemical progression: prostate-specific antigen (PSA) was increased for 3 consecutive times at an interval of 1 week or more, and increased by more than 50% compared with the lowest value for 2 consecutive times, with PSA \> 2 g/L.Or imaging progress: 2 or more new lesions or soft tissue lesions conforming to solid tumor response evaluation criteria were found on bone scan; 5. The functional level of organs must meet the following requirements (no blood transfusion or hematopoietic growth factor treatment was received within 2 weeks before routine blood screening) : * the ANC ≧ 1.5 x 109 / L; * PLT ≧ 80 x 109 / L; * Hb ≧ 90 g/L; 1.5 x ULN - TBIL ≦; * ALT and AST≦2.5×ULN; * 1.5 x ULN Cr ≦; * GFR ≧ 60 ml/min / 1.73 m2. 6. According to the researcher's judgment, it can comply with the experimental scheme; 7. In addition, in accordance with the requirements of regulatory authorities, research centers and relevant departments, and based on the judgment of researchers, you shall be tested for COVID-19 screening when necessary; 8. Volunteer to participate in this clinical trial, understand the study procedures and have signed informed consent.
Exclusion criteria
ubjects who meet any of the following criteria will not be admitted to the study: 1. Any previous anti-tumor therapy (including radiotherapy, chemotherapy, surgery, molecular targeted therapy, immunotherapy, etc.), except ADT therapy, shall be completed until the washout period of the first drug administration in this study is \<4 weeks; 2. Plan to receive any other anti-tumor therapy during the study; 3. As subjects, to participate in other drug clinical trials, the last trial drug administration is less than 4 weeks from the first administration of the drug in this study (except for the patients who have participated in ADT treatment before and have been out of the group, and the subjects who are still giving free ADT treatment); 4. The presence of intracerebral tumor lesions according to imaging diagnosis; 5. Have a history of epilepsy, or have diseases that can induce epileptic seizures within 12 months before the first administration of the drug in this study (including a history of transient ischemic attack, cerebral stroke (except cerebral ischemia lesions found by simple imaging examination), and need to be hospitalized with cerebral trauma and consciousness disorder); 6. Active heart disease, including severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, and drug-requiring ventricular arrhythmias, within 6 months prior to the first administration of the drug in this study; 7. Inability to swallow, chronic diarrhea and ileus, history of gastrointestinal surgery, or other factors affecting drug use and absorption as determined by the investigator; 8. Patients with active HBV or HCV infection (HBsAg positive and virus copy number ≥500 IU/mL, HCV antibody positive and HCV RNA higher than the lower limit of analytical method detection) and active syphilis; 9. A history of immunodeficiency (including HIV positive, other acquired or congenital immunodeficiency diseases) or a history of organ transplantation; 10. Patients who were unwilling to use effective contraceptive methods during the whole study treatment period and within 3 months after the last administration; 11. Allergic constitution, including a history of severe drug allergy or drug allergy; 12. Screening for excessive smoking in the first 6 months (≥5 cigarettes/day) or smoking within 48 hours before the first dose, or not interrupting smokers during the main study trial, and screening for drug use in the first 3 months with a history of drug abuse or positive drug abuse screening; 13. has a history of alcoholism or within 6 months prior to screening often drinkers, namely the essence of drinking more than 14 units of alcohol a week (1 = 285 mL of alcohol content of 5% beer or 25 mL of 40% alcohol liquor or 100 mL wine alcohol content of 12%) or within 48 h before taking the medicine for the first time drinking, or D - 1 in the alcohol breath test positive, or the body can't stop alcohol intake during the study period; 14. Use of any vitamin product, health product or herb 14 days prior to the first administration; 15. Ingestion of grapefruit or fruit juice products such as grapefruit, foods or beverages containing caffeine, xanthine or alcohol within 48 hours before taking the study drug;Strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion; 16. Within 2 weeks before the first drug uptake, uptake transporter P-GP, BCRP, OATP1B1/1B3 or MATE1/2-K inhibitors were used, or drugs affecting gastric acid secretion.(Annex I); 17. abnormal coagulation function at screening stage (INR \>1.5 or prothrombin time (PT) \> ULN+4 seconds or APTT\> 1.5uln), bleeding tendency or thrombolytic therapy; 18. Patients with a history of fainting needle or blood, have difficulty in blood collection or cannot tolerate vein puncture for blood collection; 19. Concomitant diseases (such as poorly controlled hypertension, severe diabetes, thyroid disease, psychosis, etc.) or any other conditions that, in the investigator's judgment, would seriously endanger the patient's safety or affect the patient's completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Summary of Pharmacokinetic parameters Maximum Plasma concentration (Cmax) for digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 |
| Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to any time before the last quantifiable concentration(AUC0-t)for digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 |
| Summary of Pharmacokinetic parameters Area Under the Plasma Concentration-time Curve form 0 to infinite time(AUCinf)for digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CL/F of digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 | — |
| Tmax of digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 | — |
| Vz/F of digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 | — |
| incidence of adverse events/serious adverse event | From ICF signing date to approximate 2 months | safety evaluation based on NCI-CTC AE 5.0 |
| T1/2 of digoxin, Rosuvastatin calcium, metformin hydrochloride | For digoxin and Rosuvastatin calcium group：Day1 and Day22；For metformin hydrochloride group：Day1 and Day19 | — |
Countries
China
Contacts
Primary ContactHaitao Niu
Backup ContactYu Cao
Outcome results
None listed